cupure logo
GSK to Acquire US Lung Cancer Drug Firm Nuvalent for $8 Billion
Independent

GSK to Acquire US Lung Cancer Drug Firm Nuvalent for $8 Billion

GSK is acquiring US lung cancer drug specialist Nuvalent for $8 billion, aiming to expand its oncology portfolio. This marks GSK's largest deal in over a decade and an early success for CEO Miels.

Comments

Read this story in other languages

Covered by the press in 4 countries

Among the outlets we follow

  • United Kingdom3
  • Germany1
  • Spain1
  • Türkiye1

Similar News from External Sources

How we write our stories →

Cupure writes the day's most important stories in seven languages. The name comes from the French 'coupure de journal' — a newspaper clipping — our promise of concise, relevant news.

For advertising inquiries, content suggestions, or to flag a concern about a news item or content, you can reach us. We value your feedback. Contact form